The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
All News
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.
Numerous previous studies have questioned the efficacy or protection afforded by hydroxychloroquine (HCQ) for COVID-19 and studies have show that HCQ has failed when given as post-exposure prophylaxis to health care workers (HCWs). A new randomized controlled trial has shown that HCQ failed when given as 8 weeks of pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19 patients.
CDC reports that since June 2020 individuals infected with COVID-19 have largely been young adults in the 20-29 year age bracket. Moreover, younger adults appeared to be driving community transmission of COVID-19.
JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.
Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August.
